JANX-007 is a fusion protein commercialized by Janux Therapeutics, with a leading Phase I program in Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of JANX-007’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for JANX-007 is expected to reach an annual total of $69 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
JANX-007 is under development for the treatment of metastatic castration resistant prostate cancer (mCRPC). The drug candidate is a bi-specific T cell engager (TCE) which acts by targeting cells expressing prostate specific membrane antigen (PSMA) and T cells. It is being developed based on Tumor Activated T Cell Engager (TRACTr) technology. It is administered through intravenous route.
Janux Therapeutics Overview
Janux Therapeutics (Janux) is a clinical-stage biopharmaceutical company that develops novel immunotherapies to treat cancer. The company’s novel proprietary platforms T cell engager (TRACTr), and tumor activated immunomodulator (TRACIr) facilitate the manufacturing of monoclonal antibodies that delivers drug candidates. Janux products pipeline includes JANX007, JANX008, TROP2 and JANX009 that target prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2) and solid tumors (JANX009). The company product pipelines are used to treat colorectal cancer, head and neck cancer, non-small cell lung cancer, and other solid tumors. It works in collaboration with Merck Sharp and Dohme Corporation to develop TRACTr product candidates. Janux is headquartered in San Diego, California, the U.S.
The company reported revenues of (US Dollars) US$8.6 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$3.6 million in FY2021. The operating loss of the company was US$67.1 million in FY2022, compared to an operating loss of US$32.9 million in FY2021. The net loss of the company was US$63.1 million in FY2022, compared to a net loss of US$32.7 million in FY2021. The company reported revenues of US$2.5 million for the third quarter ended September 2023, compared to a revenue of US$1.1 million the previous quarter.
For a complete picture of JANX-007’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.